Tykerb tablets

Tykerb (Lapatinib) tablets is manufactured by GSK.

Tykerb (Lapatinib) tablets is available in strength of 250mg

Tykerb (Lapatinib) tablets comes in a box of 7x6 tablets.

Tykerb (Lapatinib) is a kinase inhibitor. Tykerb (Lapatinib) is indicated in combination with capecitabine, for the treatment of patients with advanced or metastatic breast cancer. Tykerb (Lapatinib) may cause a condition that affects the heart rhythm (QT prolongation). Tykerb (Lapatinib) should be discontinued in patients with a decreased left ventricular ejection fraction (LVEF) that is Grade 2 or greater by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v3) and in patients with an LVEF that drops below the institution’s lower limit of normal.